Stock Research: Bristol-Myers Squibb

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Bristol-Myers Squibb

NYSE:BMY US1101221083
72
  • Value
    29
  • Growth
    49
  • Safety
    Safety
    94
  • Combined
    63
  • Sentiment
    63
  • 360° View
    360° View
    72
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases. It operates in oncology, hematology, immunology, and neuroscience. The company operates globally. In the last fiscal year, the company had a market cap of $94,489 million, profits of $36,351 million, revenue of $48,300 million, and 34,100 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 72 (better than 72% compared with alternatives), overall professional sentiment and financial characteristics for the stock Bristol-Myers Squibb are above average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Bristol-Myers Squibb. The consolidated Value Rank has an attractive rank of 94, which means that the share price of Bristol-Myers Squibb is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 94% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 63, which means that professional investors are more optimistic about the stock than for 63% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 49, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 29, meaning the company has a riskier financing structure than 71 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
Dividends USA
Diversity USA
D.J. US Pharmaceutical
S&P 500
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
94 92 92 97
Growth
49 43 7 27
Safety
Safety
29 30 31 35
Sentiment
63 40 68 51
360° View
360° View
72 51 39 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
7 9 10 34
Opinions Change
80 12 48 64
Pro Holdings
n/a 88 87 40
Market Pulse
54 79 78 68
Sentiment
63 40 68 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
94 92 92 97
Growth
49 43 7 27
Safety Safety
29 30 31 35
Combined
63 58 29 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
91 83 91 96
Price vs. Earnings (P/E)
51 43 37 40
Price vs. Book (P/B)
29 23 19 35
Dividend Yield
98 98 98 98
Value
94 92 92 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
6 6 25 11
Profit Growth
98 100 31 47
Capital Growth
28 17 26 48
Stock Returns
51 61 37 73
Growth
49 43 7 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
13 16 24 34
Refinancing
27 27 25 25
Liquidity
75 75 76 66
Safety Safety
29 30 31 35

Similar Stocks

Discover high‑ranked alternatives to Bristol-Myers Squibb and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.